Renee A Cowan1, Destin R Black1, Lien N Hoang2, Kay J Park2, Robert A Soslow3, Floor J Backes4, Ginger J Gardner5, Nadeem R Abu-Rustum5, Mario M Leitao5, Eric L Eisenhauer4, Dennis S Chi6. 1. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 2. Gynecology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 3. Gynecology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. 4. Department of Gynecologic Oncology, The James Cancer Hospital and Solove Research Institute, Ohio State University Medical Center, 460 West 10(th) Avenue, Columbus, OH 43210, USA. 5. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. 6. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. Electronic address: chid@mskcc.org.
Abstract
OBJECTIVE: The objective of this prospective pilot study was to assess the clinical and histologic effects of topical imiquimod therapy on recurrent extramammary Paget's disease of the vulva. METHODS: Patients with biopsy-proven recurrent extramammary Paget's disease presenting to the gynecology outpatient services at two participating institutions were recruited for conservative treatment with 5% imiquimod cream from 2007 to 2011. The topical cream was to be applied 3 times per week for 12weeks. Punch biopsy and photography were performed at baseline and at the 12-week time point. RESULTS: Eight patients from two institutions were enrolled. Complete clinical and histologic response was achieved in 6 (75%) patients by the 12-week follow-up appointment. Of the two remaining patients, one had a complete clinical response but no significant histologic response; the other patient was removed from the study protocol secondary to intolerable local irritation. Two patients continue to have no evidence of disease after a median follow-up of 35months. Five are alive with disease. No patients progressed to invasive cancer while receiving therapy. CONCLUSION: Topical 5% imiquimod cream is a safe and feasible option for women suffering from recurrent extramammary Paget's disease of the vulva, and should be considered as a viable alternative to surgical management. Given the rare nature of this disease, additional multi-institutional prospective studies should be conducted to explore the efficacy of this treatment regime.
OBJECTIVE: The objective of this prospective pilot study was to assess the clinical and histologic effects of topical imiquimod therapy on recurrent extramammary Paget's disease of the vulva. METHODS:Patients with biopsy-proven recurrent extramammary Paget's disease presenting to the gynecology outpatient services at two participating institutions were recruited for conservative treatment with 5% imiquimod cream from 2007 to 2011. The topical cream was to be applied 3 times per week for 12weeks. Punch biopsy and photography were performed at baseline and at the 12-week time point. RESULTS: Eight patients from two institutions were enrolled. Complete clinical and histologic response was achieved in 6 (75%) patients by the 12-week follow-up appointment. Of the two remaining patients, one had a complete clinical response but no significant histologic response; the other patient was removed from the study protocol secondary to intolerable local irritation. Two patients continue to have no evidence of disease after a median follow-up of 35months. Five are alive with disease. No patients progressed to invasive cancer while receiving therapy. CONCLUSION: Topical 5% imiquimod cream is a safe and feasible option for women suffering from recurrent extramammary Paget's disease of the vulva, and should be considered as a viable alternative to surgical management. Given the rare nature of this disease, additional multi-institutional prospective studies should be conducted to explore the efficacy of this treatment regime.
Authors: Linda C Wang; Anita Blanchard; Diane E Judge; Allan A Lorincz; Maria M Medenica; Shail Busbey Journal: J Am Acad Dermatol Date: 2003-10 Impact factor: 11.527
Authors: Cynthia M Fehres; Sven C M Bruijns; Astrid J van Beelen; Hakan Kalay; Martino Ambrosini; Erik Hooijberg; Wendy W J Unger; Tanja D de Gruijl; Yvette van Kooyk Journal: Eur J Immunol Date: 2014-06-24 Impact factor: 5.532
Authors: Destin Black; Carmen Tornos; Robert A Soslow; Christopher S Awtrey; Richard R Barakat; Dennis S Chi Journal: Gynecol Oncol Date: 2006-10-24 Impact factor: 5.482
Authors: Marina Stasenko; Gowtham Jayakumaran; Renee Cowan; Vance Broach; Dennis S Chi; Anthony Rossi; Travis J Hollman; Ahmet Zehir; Nadeem R Abu-Rustum; Mario M Leitao Journal: JCO Precis Oncol Date: 2020-09-15
Authors: Cherry O Onaiwu; Mila Pontremoli Salcedo; Suzana A Pessini; Mark F Munsell; Elizabeth E Euscher; Kellie E Reed; Kathleen M Schmeler Journal: Gynecol Oncol Rep Date: 2016-12-30
Authors: Michelle van der Linden; Kim Meeuwis; Colette van Hees; Eleonora van Dorst; Johan Bulten; Tjalling Bosse; Joanna IntHout; Dorry Boll; Brigitte Slangen; Manon van Seters; Marc van Beurden; Mariëtte van Poelgeest; Joanne de Hullu Journal: JMIR Res Protoc Date: 2017-09-06